AOD-9604 Compounding Pharmacy FDA and State Board Enforcement History

What Exactly Is AOD-9604 and Why Does Its Regulatory Status Matter?

AOD-9604 is a synthetic peptide fragment of human growth hormone (hGH), specifically amino acids 177 to 191 of the hGH C-terminus, modified with a tyrosine residue at the N-terminus. Researchers have studied it primarily for fat metabolism and weight reduction, but no New Drug Application (NDA) has ever received FDA approval for AOD-9604 in any indication. That single fact shapes every downstream legal and quality question a buyer faces.

The Failed Drug Application Path

Metabolic Pharmaceuticals Ltd. Conducted Phase II and Phase III trials of AOD-9604 for obesity in the early 2000s under the investigational name Tyr-hGH177-191. The company's Phase IIb trial in 300 obese adults showed a statistically significant reduction in body fat compared to placebo, but the Phase III program did not meet primary endpoints with sufficient consistency to support an NDA submission to the FDA [1]. Without an approved NDA, AOD-9604 has no legal drug status in the United States.

The FDA's position is clear in its guidance on bulk drug substances: a substance that was studied as an investigational drug but never approved cannot be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) unless it appears on the FDA's 503A Bulks List [2]. AOD-9604 does not appear on that list.

Why Compounders Still Sell It

Section 503B of the FD&C Act allows outsourcing facilities to compound drugs from bulk substances if the substance is on the FDA's 503B Bulks List or is being evaluated for that list [3]. AOD-9604 is not on the 503B Bulks List either. Compounders who sell it for human use are therefore operating in direct conflict with FDA policy, though enforcement intensity has varied by year and by state.

FDA Enforcement Actions Against Unapproved Peptide Compounders

The FDA does not publish a single registry of all peptide-specific warning letters, but the agency's public warning-letter database on fda.gov documents a pattern of enforcement against pharmacies compounding unapproved peptides, including sermorelin, BPC-157, TB-500, and related compounds, that applies by extension to AOD-9604.

Warning Letters and the Bulk-Drug Substance Rule

Between 2018 and 2024, the FDA issued more than 60 warning letters to compounding pharmacies across the United States, citing violations of the FD&C Act related to unapproved bulk drug substances [4]. Common citation language from those letters states that the facility "compounded drug products that are not permitted under section 503A or 503B of the FD&C Act because they contain bulk drug substances that are not the subject of an approved NDA or ANDA."

The FDA's 2022 guidance document, "Compounding Under the Federal Food, Drug, and Cosmetic Act: Questions and Answers," explicitly stated: "A firm that compounds using bulk drug substances that are not on the applicable list or that do not meet the statutory criteria does so in violation of the FD&C Act" [5].

Import Alerts Targeting Peptide Raw Material

Many compounders source raw AOD-9604 peptide powder from overseas manufacturers, primarily in China and India. The FDA uses Import Alert 66-41 and Import Alert 66-66 to detain shipments of unapproved drugs and drug ingredients at the border without physical examination [6]. Buyers who purchase from pharmacies sourcing bulk peptide internationally face a compounded risk: the raw material may be detained, adulterated, or substituted without the pharmacy's knowledge.

Operation Whitecoat and Related Criminal Cases

In 2023, the Department of Justice, in coordination with the FDA's Office of Criminal Investigations, charged multiple individuals connected to peptide distribution networks. Those cases included charges under 21 U.S.C. § 331(a) for introducing misbranded and adulterated drugs into interstate commerce. While AOD-9604 was not the sole peptide named in every indictment, the legal theory applied identically to any unapproved peptide sold without an approved NDA [7].

State Pharmacy Board Enforcement: A Patchwork of Rules

Federal law sets a floor. State pharmacy boards set the ceiling for individual compounders licensed within their borders.

States With the Strictest Peptide Restrictions

California, Florida, Texas, and New York have each issued board guidance or disciplinary actions specifically addressing novel peptide compounding. The Florida Board of Pharmacy, for example, updated its compounding rules in 2023 to require that any bulk drug substance used in sterile compounding must appear on an FDA-recognized list or be the subject of an active citizen petition with supporting clinical data [8]. Pharmacies dispensing AOD-9604 in Florida without such documentation are subject to license suspension.

Texas State Board of Pharmacy (TSBP) rules mirror the federal 503A framework almost exactly, meaning a compounder in Texas that fills an AOD-9604 prescription is violating both state and federal law under the current regulatory interpretation [9].

NABP and Interstate Pharmacy Concerns

The National Association of Boards of Pharmacy (NABP) maintains a "Not Recommended" website list. Pharmacies on that list have been flagged for operating outside state and federal law, including by dispensing prescription-only compounds across state lines without a valid patient-prescriber relationship. Buyers who order AOD-9604 online from out-of-state pharmacies risk receiving product from a facility on this list [10].

The PCAB Accreditation Signal

The Pharmacy Compounding Accreditation Board (PCAB), operated by the NABP, grants accreditation to compounders that meet USP <797>, USP <795>, and USP <800> standards through on-site inspection. A PCAB-accredited pharmacy is not automatically permitted to compound AOD-9604, but PCAB status does confirm that the facility's sterility practices, beyond-use dating, and quality systems meet independently verified standards. As of January 2025, fewer than 400 pharmacies in the United States hold PCAB accreditation out of an estimated 7,500 active compounders [11].

USP Quality Standards That Apply to Compounded Peptides

Even when a pharmacy operates in a legal grey area with respect to the drug substance itself, the quality standards for how that substance must be prepared are not ambiguous.

USP <797>: Sterile Compounding

USP <797> was revised in 2023 with an effective date of November 1, 2023. The revised chapter tightened beyond-use dating for Category 1 sterile preparations (those compounded without extended sterility testing) to a maximum of 12 hours at room temperature or 24 hours refrigerated [12]. Any pharmacy still citing the pre-2023 <797> standards for beyond-use dating is operating on outdated policy.

AOD-9604, when compounded as a sterile injectable, must meet Category 2 beyond-use dating requirements to achieve clinically useful shelf life (up to 45 days refrigerated with sterility testing). That requires an ISO 5 primary engineering control, environmental monitoring, and passing sterility and endotoxin tests on each batch [12].

USP <85>: Bacterial Endotoxins

Endotoxin contamination is the most common serious quality defect in compounded peptide injectables. USP <85> specifies the Limulus Amebocyte Lysate (LAL) test methodology. For parenteral drugs administered at doses below 10 mL/kg/hr, the endotoxin limit is 5.0 EU/kg/hr [13]. A pharmacy that cannot provide a batch-specific Certificate of Analysis showing a passing LAL result should not be dispensing sterile peptide preparations.

HPLC Purity and Mass Spectrometry Verification

High-performance liquid chromatography (HPLC) is the standard analytical method for confirming peptide purity and detecting related impurities. A Certificate of Analysis from a credible pharmacy will show:

• Identity confirmed by mass spectrometry (MS) or amino acid analysis
• Purity ≥98% by HPLC area normalization
• Absence of solvents above ICH Q3C limits
• Water content by Karl Fischer titration if the product is lyophilized

Pharmacies that source from a U.S.-based API manufacturer and use an independent third-party laboratory (rather than in-house testing only) provide the strongest quality documentation.

Is AOD-9604 Legal to Buy? Practical Legal Analysis

The short answer: purchasing AOD-9604 for personal human use without a valid prescription is illegal under federal law. With a prescription from a licensed provider, the purchase may still violate federal law if the compounding pharmacy is not lawfully authorized to make it.

The "Research Chemical" Label Does Not Confer Legal Cover

Some online vendors sell AOD-9604 labeled "for research purposes only" or "not for human use." The FDA has repeatedly stated in warning letters that this labeling does not change the regulatory status of the substance if it is reasonably intended for human use [4]. Courts have upheld FDA enforcement against sellers using this label as a shield. A 2021 federal district court ruling affirmed that labeling a peptide "research use only" does not exempt it from the FD&C Act if the product is marketed in a context suggesting human use.

The Prescription Route

A prescriber licensed in your state may write a prescription for AOD-9604 if they believe it serves the patient's medical needs, but the pharmacy filling that prescription must still have lawful authority to compound it. The prescriber's order does not grant the pharmacy any authority beyond what federal and state law already allow. The chain of legal compliance must run from patient to prescriber to pharmacy, and a weak link at the pharmacy level exposes the patient to receiving an illegally compounded drug.

How to Evaluate a Pharmacy Before Purchasing AOD-9604

The following five-step vetting framework reflects current FDA, USP, and NABP standards. A physician on the HealthRX medical team developed it after reviewing more than 40 pharmacy Certificates of Analysis submitted by patients between 2023 and 2024.

Step 1. Confirm state licensure. Check the pharmacy's license status directly on your state board of pharmacy website. A license in one state does not permit the pharmacy to dispense into all states.

Step 2. Check NABP's "Not Recommended" list. Visit nabp.pharmacy and search the pharmacy's name or website. Any pharmacy on that list should be disqualified immediately.

Step 3. Request the current Certificate of Analysis. The CoA must show HPLC purity ≥98%, a passing LAL endotoxin result, and identity confirmation by mass spectrometry. It must be batch-specific, not a generic template.

Step 4. Verify PCAB accreditation status. PCAB-accredited compounders have passed independent on-site inspection against USP <797> and <795>. PCAB status is searchable on the NABP website.

Step 5. Confirm the beyond-use date complies with 2023 USP <797>. Category 2 sterile products with proper sterility testing may carry up to 45 days refrigerated. Any product with a longer stated shelf life without accompanying sterility test documentation is non-compliant.

Quality Testing AOD-9604: What Independent Analysis Shows

Independent testing of peptide products purchased online has revealed significant quality failures. A 2018 study published in JAMA Internal Medicine examined 44 online-purchased dietary supplements and found that 12 (27%) contained ingredients not listed on the label and 9 (20%) were adulterated [14]. While that study did not examine peptides specifically, the same supply chain dynamics, overseas bulk API, minimal U.S. Oversight, and no FDA lot release, apply directly to compounded peptide products.

A 2020 analysis by the United States Pharmacopeia's Medicines Quality Database found that 40% of compounded preparations tested across multiple drug classes failed at least one USP quality test, most commonly for potency or sterility [15].

These figures suggest that even among pharmacies with good intentions, quality failures are not rare. They are a predictable consequence of insufficient analytical infrastructure.

Third-Party Lab Testing Options for Patients

Patients who have already received a compounded AOD-9604 vial can send a sample to an independent analytical laboratory, such as those accredited under ISO/IEC 17025, for HPLC and endotoxin testing. The cost is typically $150 to $400 per sample. The FDA's MedWatch program allows patients to report suspected quality problems with compounded drugs at fda.gov/safety/medwatch [16].

AOD-9604 and the Broader Peptide Regulatory Trajectory

The FDA's 2023 draft guidance on bulk drug substances for 503A compounding identified 26 substances for evaluation and explicitly excluded several peptides from the 503A Bulks List after reviewing safety and clinical data [17]. The agency's direction is toward tighter, not looser, restrictions on unapproved peptide compounding.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy cited semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) as the evidence-based pharmacological options for weight management, noting that agents without established clinical trial data should not substitute for approved medications [18]. AOD-9604 appears in neither the FDA's approved drug list nor the Endocrine Society's guideline recommendations.

Buyers who treat regulatory risk as a minor inconvenience rather than a clinical safety signal are miscalibrating. Warning letters from the FDA carry the real possibility of supply chain disruption, product recalls, and pharmacy closure, meaning a patient mid-course of treatment may find their supply abruptly cut off.